Hematologists, hematologist/oncologists, bone marrow transplant
specialists and other blood cancer experts at Rush share a commitment to
exploring every available path toward the best outcomes. Some patients
are seen through The Coleman Foundation Comprehensive Cancer Clinics,
which offer multidisciplinary care and allow patients to meet with all
of the specialists involved in their diagnosis and treatment during a
single session and discuss the advantages and disadvantages of various
MEET OUR TEAM
Irene Dehghan-Paz, MD is an assistant professor of internal medicine in the
Section of Hematology for the Division of Hematology, Oncology and Cell Therapy
at Rush University Medical Center. Dr. Dehghan-Paz
received a Bachelor of Arts from Northwestern University. In 2007, she
obtained her medical degree from the University of Illinois College of
Medicine. Dr. Dehghan-Paz completed her Internal Medicine residency and Hematology
and Oncology fellowship at Rush University Medical Center. She is the
hospitalist for the malignant hematology teaching and the hematology consult
services. Dr. Dehghan-Paz speaks Spanish fluently.
Dr. Gezer is Professor of
Medicine; Senior Attending Physician of Internal Medicine; Director of the
Coagulation; Thrombosis and Anticoagulation Clinic at Rush University Medical
Center; He received his medical degree from Hacettepe Medical School in Ankara,
Turkey, and subsequently completed his residency in internal medicine and a
fellowship in hematology at Wayne State University in Detroit, Michigan.
Dr. Gezer is an active member of many medical societies, including the American
College of Physicians, the Cell Kinetics Society, and the American Society of
Hematology. Dr. Gezer is the author and co-author of numerous articles
that appear in such journals as Leukemia Research, Experimental Hematology, and
Blood. He is an expert in the area of Coagulation and Thrombosis.
Dr. Gregory holds the Elodia Kehm Chair of
Hematology and is Professor of Medicine at Rush University Medical Center/Rush
University, Chicago, Illinois. She is a hematologist whose specializes in the
diagnosis and treatment of the hematologic malignancies including Hodgkin and
non-Hodgkin lymphoma, chronic leukemia, myelodysplastic syndromes (MDS),
myeloma, Waldenström’s macroglobulinemia and monoclonal gammopathy of
undetermined significance (MGUS).
Gregory’s career has been directed toward patient care, teaching, research and
administration. She received numerous awards for teaching and services to
patients, including the “Excellence in Medicine Award” from Rush’s Department
of Internal Medicine and the “Chicago HOPE Award” from the Lymphoma Research
Foundation. Her research interests include Hodgkin and non-Hodgkin lymphomas,
leukemias and myelomas, especially using novel approaches of immunotherapy. Dr.
Gregory has been involved in several radioimmunotherapy trials in non-Hodgkin
is the Vice-Chair of the Medical Affairs Board and member of the Scientific
Advisory Board of the Lymphoma Research Foundation. She has held the following
posts in the American Society of Hematology: senior editor on two editions of
the American Society of Hematology’s “Self Assessment Program Book; member of
the Continuing Medical Education Accreditation Subcommittee; and faculty member
in the “Consult a Colleague” Program. She is a member of the Scientific
Advisory Boards of the International Chicago Lymphoma Symposium and the
Leukemia/Lymphoma Society of America.
has chaired or co-chaired many national and international symposia on
hematologic malignancies. She served as the chairperson for medical educational
programs. She is the founder and national chair of the “Lymphoma Rounds:
Chicago.” She has authored or coauthored 528 manuscripts, books, book chapters
Reem Karmali, MD, is a full time Assistant Professor with the Division of
Hematology, Oncology and Cell Therapy. Dr. Karmali graduated from
the Schulich School of Medicine at the University of Western
Ontario in London, Canada. She completed her Internal
Medicine residency and Hematology-Oncology fellowship at Rush University
Medical Center in Chicago. Dr. Karmali received a Master of Science
degree in Clinical Research from Rush Medical College. She is
a hematologist who treats benign and malignant blood disorders, specializing in
lymphoma diagnosis, treatment and survivorship. Dr. Karmali participates
in the Coleman Comprehensive Lymphoma Clinic. She is the Principal
Investigator for numerous clinical trials in lymphoma and heads the
collaborative effort in treating and conducting research focused on patients
with primary CNS lymphoma across the academic institutions in
Chicago. She also heads translational research efforts in lymphoma
and leukemia. Dr. Karmali holds memberships in the American Society of
Hematology, and the American Society of Clinical Oncology.
Melissa L. Larson, MD, is an associate professor of
hematology at Rush University Medical Center. She received her MD from Rush
Medical College and completed her internal medicine residency and
hematology/oncology fellowship at Rush-Presbyterian-St. Luke's Medical Center
(Rush University Medical Center). Dr. Larson's clinical practice focuses on
acute leukemias and other hematologic disorders. She is the director of the
Leukemia Program and the Leukemia Comprehensive Clinic at Rush University
Dr. Larson holds memberships in the American Society of Hematology and
American Society of Clinical Oncology. She has authored or co-authored numerous articles that appear in several journals.
Agne Paner, MD, is an assistant professor of medicine at Rush University Medical Center, division of hematology. She subspecializes in benign hematology and multiple myeloma. Dr. Paner is the director of the Coleman Foundation Comprehensive Multiple Myeloma
Clinic. She is a principal investigator of several clinical trials for multiple
Dr. Paner is a diagnostic bone marrow biopsy director. She is involved in research of harvesting hematopoietic stem cells and utilizing them for treatment of cardiovascular disease.
Dr. Paner speaks fluent Lithuanian.
Jamile M. Shammo, MD, is an associate
professor of medicine and pathology, Section of Hematology and Stem Cell
Transplantation, Division of Hematology/Oncology, at Rush University Medical
Center in Chicago, Illinois, where she spearheads the MDS/MPN/Bone Marrow
Failure Program. She is involved in research activities and administration, as
a principal investigator of clinical trials in her area of expertise, and as a
co-chair for the protocol review and monitoring committee at Rush Cancer
Institute. She is recognized nationally for her expertise in bone marrow failure
syndromes, and was chosen to serve as a national coordinator for the PNH
registry. Dr. Shammo earned her medical degree with honors from Aleppo Medical School
in Syria, after which she pursued further education in the US and completed
residencies in Pathology and Internal Medicine at McGaw Medical Center of
Northwestern University in Evanston, Illinois, as well as a 3-year fellowship
in the Division of Hematology/Oncology at University of Chicago.
Dr Shammo is board certified in anatomic and clinical pathology,
internal medicine, and hematology, and board eligible in oncology. Dr Shammo is
a fellow of the American Society of Clinical Pathologists and American College
of Physicians. She received the Department of Medicine Service and Teaching
Award from Rush University Medical Center in 2003. Dr. Shammo speaks fluent
Dr Shammo has authored or coauthored over 100 publications, including
abstracts, posters, book chapters and online CME activities, as well as
articles published in Blood, American Journal of Hematology, Journal of
Clinical Oncology, Clinical Lymphoma, Journal of Heart and Lung
Transplantation, Cytotherapy, and American Journal of Clinical
Pathology, among others. Additionally, she served as a reviewer for several
medical journals and as an editor for the Journal of Clinical Oncology. She
has designed and is currently involved as principal investigator for many
clinical trials related to chronic myelogenous leukemia, myeloproliferative
neoplasms, paroxysmal nocturnal hemoglobinuria, and myelodysplastic syndromes.
As an invited speaker, Dr Shammo has presented her research at national and
international meetings and conferences.
MD is the Samuel Taylor III,
MD, Professor of Oncology at Rush University Medical Center, where
he is the Director of the Section of Hematology and Associate Director, DHOC.
He received his medical degree from Trivandrum Medical College, University of
Kerala, in India and then trained in Hematology/ Oncology at the Tata Memorial
Cancer Center in Bombay. Dr. Venugopal earned a postgraduate Diploma in
Clinical Hematology at the University of London, Royal Postgraduate Medical
School, Hammersmith Hospital. Subsequently he completed residency and
fellowship in Hematology-Oncology at Rush University Medical Center.
Dr. Venugopal is actively
involved in clinical and laboratory research in leukemia and lymphoma. He has
designed and conducted studies involving translational research combining
monoclonal antibodies with cytotoxic and biologic agents in lymphoma, leukemia,
and other hematological malignancies. The major focus of his research involves
the development of novel methods of enhancing tumor response to biologic
agents. In the laboratory, he has identified several cytokines that enhance the
expression of tumor cell antigens, increasing their sensitivity to monoclonal
antibodies. He has been an invited speaker at many medical institutions, both
in the United States and abroad. He has authored or co-authored 91 full-length
manuscripts, 7 book chapters, and over 240 abstracts.
Dr. Venugopal is an
active member of the American Society of Hematology, American Society of
Clinical Oncology and American Association for Cancer Research. He has received
awards from the American Society of Clinical Oncology/American Association for
Cancer Research, the Cure For Lymphoma Foundation and the Berlex Oncology
Foundation. He also serves on the Advisory Board of the Leukemia Society
Rush offers compassionate care for people with a variety of benign blood disorders and cancers that develop in bone marrow, blood and lymph nodes, including the following:
If you have a suspected or diagnosed cancer, we are here to help. Call (312) 563-2320 to schedule an initial visit or an appointment for a second opinion.
Physicians carefully evaluate each patient to ensure an accurate diagnosis. Some blood cancers can be diagnosed readily by taking the patient’s medical history into account, performing a physical examination and looking at blood count results. Others may take a long time and many tests, including a bone marrow study, to detect. Blood cancer specialists at Rush use some of the following tools for diagnosis:
- Diagnostic bone marrow procedure, an analysis of bone marrow samples taken through a bone marrow biopsy.
- Genetic testing, which may help identify people who are at an increased risk for developing certain types of cancer.
- Ultrasound testing, high-frequency sound waves that create images of organs and other systems within the body.
Rush offers a full range of treatment for hematologic cancers, from standard therapies to innovative treatment options, and new options are being explored every day.
Physicians at Rush are involved in clinical trials evaluating new treatment options for hematologic cancers. Through clinical trials, some patients can access experimental treatments that are not otherwise available.
Accreditation and Recognition
Rush University Cancer Center
1725 W. Harrison St.
Professional Building II
Chicago, IL 60612
Phone: (312) 942-5904
Fax: (312) 942-3192
Rush Cancer Care in Oak Park
610 S. Maple Avenue
Oak Park, IL 60304
Phone: (708) 660-6607
Fax: (708) 660-6602
Rush Cancer Care in Lisle
430 Warrenville Road
Lisle, IL 60532
Phone: (630) 724-8700
Fax: (630) 724-8702